Numerous studies have demonstrated that post‐chemotherapy prognoses of NSCLC patients with HER2 alterations are unfavorable, with a median PFS of 4.9–5.9 months and median OS of 9.9–10.7 months in first‐line or second‐line treatment.17, 18, 19, 20. Here, ERBB2 is linked to non-small cell lung carcinoma.